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ABSTRACT The treatment options for cancer patients include
surgery, chemotherapeutics, radiation therapy, antibody therapy
and various combinations of these therapies. The challenge with
each therapy is finding the balance between maximizing the anti-
tumor efficacy while minimizing the dose limiting toxicities. Anti-
bodies, unlike small molecule chemotherapeutics, selectively bind
to cell surface tumor antigens and can be used to deliver
radionucleotides or small molecule chemotherapeutic drugs di-
rectly to the tumor. Advances in antibody engineering, linker
chemistry and the identification of potent cytotoxic drugs led to
the recent approval of two antibody drug conjugates to treat
breast cancer and lymphoma patients. We will discuss how the
observations from the clinical development of antibody drug
conjugates can guide the preclinical development of the next
generation of antibody drug conjugates.
KEYWORDS antibodydrug conjugate . preclinical . site specific
ABBREVIATIONS
ALCL Anaplastic large cell lymphoma
ADC Antibody drug conjugate
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CL2A maleimido-[short PEG]-Lys-PABOCO-20-O-SN-38
DAR Drug to antibody ratio







NNAA Non-natural amino acid
NSCLC Non-small cell lung cancer
PBD Pyrrolobenzodiazepine
PDX Patient derived xenograft
PK/PD Pharmacokinetic/Pharmacodynamic
Q3W Every 3 weeks
RCC Renal cell cancer
SCC Squamous cell carcinoma







Small molecule chemotherapeutics and antibodies are com-
monly used to treat cancer patients. Small molecule chemo-
therapeutics, such as doxorubicin, paclitaxel and vinblastine,
are delivered systemically, have relatively short serum half-
lives and do not specifically target tumor cells. These mole-
cules not only kill rapidly dividing tumor cells but they can also
kill some normal cells, which results in various dose limiting
toxicities (DLTs), such as neutropenia. DLTs reduce the
amount of drug that can be administered to a patient which
can reduce the effectiveness of a drug.
Antibodies are also delivered systemically but tend to have
long serum half-lives and selectively bind to tumor cells.
Antibody drug conjugates (ADCs) are a combination of the
small molecule chemotherapeutic and the antibody thus
allowing the selective delivery of the small molecule chemo-
therapeutic drugs to tumor cells and not normal cells.
Although average Drug/Antibody Ratios (DAR) are typi-
cally in the range from 2 to 4 drugs per antibody, most ADCs
in clinical development today are a mix of antibodies carrying
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0 to as many as 12 cytotoxic drugs covalently conjugated to
specific amino acids on the antibody via a chemical linker.
ADCs bind to cell surface antigens; they are typically inter-
nalized by the cells and processed by the lysosomes where the
cytotoxic drugs are released into the cytotsol. Once the drugs
are released from the lysosomes, they bind to their intracellu-
lar target, disrupt a critical cellular process and kill the cell.
The preclinical development of ADCs involves several
steps which include the identification of the tumor antigen,
the discovery and characterization of an antibody against the
tumor antigen, the identification of the appropriate cytotoxic
drug, the conjugation of the cytotoxic drug to the antibody
and the characterization of the amount of aggregate and other
physiochemical properties of the ADC. The preclinical eval-
uation of ADCs includes antibody/antigen binding studies,
in vitro cytotoxic studies, in vivo anti-tumor efficacy studies,
pharmacokinetic and the toxicology studies in rodent and
non-human primates.
The observations from the clinical development of ADCs
have been crucial in refining the preclinical development of
ADCs. Improvements in antibody engineering, potency of
cytotoxic drugs and improvements in the linker chemistry lead
to the current generation of ADCs. We will discuss how data
from the current clinical studies can be used to improve the
preclinical development of the next generation of ADCs.
ADCS: A HISTORICAL PERSPECTIVE
Paul Ehrlich, the German physician and scientist, de-
scribed the concept of delivering a toxophore, a cytotoxic
drug, selectively to tumors. ADCs are the embodiment of
this concept. The first generation of ADCs used common
chemotherapeutic drugs such as methotrexate, vinblastine
and doxorubicin as cytotoxic drug payloads. KS1/4 and
BR96 were the first antibodies to enter clinical develop-
ment as ADCs.
KS1/4 was a murine IgG2a antibody against a 40 and
42 kD glycoprotein expressed by the human lung adenocar-
cinoma cell line, UCLA-P3 (1). The KS1/4 antigen is
expressed by several cancers including ovarian, lung, pancre-
atic and colorectal cancers. KS1/4 was conjugated to metho-
trexate (KS1/4-methotrexate) or vinblastine (KS1/4-
DAVLB) (2,3). There were 6 molecules of methotrexate and
4 to 6 molecules of vinblastine per antibody on lysines using
hemisuccinate linkers. Preclinical in vivo anti-tumor efficacy
was reported for the KS1/4-methotrexate and the KS1/4-
DAVLB ADCs but no significant clinical responses were
observed. Patients treated with the KS1/4 antibody or
KS1/4 ADCs produced an antibody response against the
mouse antibody, also known as a human anti mouse antibody
(HAMA) response. Although the HAMA response has been
reported to result in rapid systemic clearance of the antibody
thus rendering the antibody or in this case ADC ineffective,
high serum levels of the KS1/4 antibody were reported in
patients treated with the higher doses of the KS1/4 antibody
or ADCs. Subsequent ADCs used chimeric, humanized or
fully human antibodies to reduce the patient’s immune re-
sponse against the antibody.
BR96-Doxorubicin (SGN-15) was licensed by Seattle Ge-
netics from Bristol-Meyer Squibb (BMS) (4). SGN-15 was a
chimeric antibody against the Lewis Y (CD174) antigen that
was conjugated to doxorubicin (adriamycin) using an acid
labile, 6-maleimidocaproyl hydrazone linker (5,6). In preclin-
ical studies, SGN-15 was able to selectively kill Lewis Y
expressing cells in both in-vitro cytotoxicity and in in-vivo tumor
efficacy studies yet it was unable to show statistically significant
clinical benefit and further development was discontinued.
The lack of clinical benefit has been attributed to several
factors including the insufficient cytotoxic potency of doxoru-
bicin, the instability of the hydrazone linker and the expression
of Lewis Y by several normal tissues. (7–9).
CMD-193, which was developed by Wyeth Pharmaceuti-
cals, Inc, was a humanized antibody (hu3S193) against the
Lewis Y antigen that was conjugated to the DNA synthesis
inhibitor, N-acetyl gamma calicheamicin dimethyl hydrazide
(Calicheamicin) using the acid labile 4-(4′-acetylphenoxy)
butanoic acid) linker (10). In preclinical studies, CMD-193,
like SGN-15, was able to kill Lewis Y expressing tumors in
both in vitro cytotoxicity studies and in vivo tumor efficacy
studies (10) . In a phase I clinical study, myelosuppression
and prolonged liver uptake which affected liver function were
the most significant adverse events (11). Further clinical devel-
opment of CMD-193 was terminated.
Gemtuzumab Ozogamacin (Mylotarg), which was also
developed by Wyeth Pharmaceuticals, Inc (now Pfizer) and
Celltech (now a part of UCB Brussels), was a humanized anti-
CD33 IgG4 antibody, conjugated to Calicheamicin via the
acid labile 4-4′-acetylphenoxy butanoic acid linker. Mylotarg
had an average of 3 molecules of Calicheamicin per
antibody and approximately 50% of the antibody did
not contain Calicheamicin (12). Despite the high amount
of unconjugated antibody, which could reduce its effec-
tiveness, Mylotarg was able to kill CD33 expressing cells
in in-vitro cytotoxicity studies and in preclinical in-vivo
tumor efficacy studies (13). Mylotarg showed promise in
clinical studies and was the first ADC to gain approval
from the food and drug administration (FDA) in May
2000. Despite the promising clinical data, Mylotarg was
eventually withdrawn from the market, in 2010, due to a
lack of efficacy and an increased number of deaths in
acute myelogenous leukemia (AML) patients as compared
to patients treated with the standard of care chemothera-
peutics (14).
Subsequent preclinical efforts to develop ADCs focused on
the identification of potent cytotoxic drugs, linker chemistries
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that provide sufficient in vitro and in vivo stability and refine-
ment of conjugation conditions to reduce the amount of
unconjugated antibody.
In 2011 Adcetris (Brentuximab vedotin) was ap-
proved by the FDA to treat systemic anaplastic large
cell lymphoma (sALCL) and Hodgkin’s lymphoma (HL).
Adcetris is a chimeric IgG1 antibody against CD30 that
is conjugated to an average of four molecules of the
cytotoxic drug, monomethyl auristatin E (MMAE), via
the thiols on cysteines using a valine-citrulline dipeptide
linker with a p-aminobenzyl alcohol (PABA) spacer.
MMAE is a potent inhibitor of cell growth in vitro.
MMAE’s average in vitro IC50 values, against a panel
of human tumor cell lines, were commonly below 1 nM
as opposed to doxorubicin which had an average IC50
value of 631 nM (15).
In 2013, Kadcyla (T-DM1) was approved by the FDA to
treat Her2 expressing metastatic breast cancer patients.
Kadcyla is a humanized IgG1 antibody against Her2 that is
conjugated to an average of 3.5 molecules of the cytotoxic
maytansine drug, N2 ′-deacetyl-N2 ′-(3-mercapto-1-
oxopropyl)-maytansine (DM1), via the amines on lysines
using the 4-[N-maleimidomethyl] cyclohexane-1-
carboxylate (MCC) linker. DM1’s average in vitro cyto-
toxicity IC50 values against several tumor cell lines were
less than 1 nM (16,17).
The clinical development of ADCs is expanding rapidly.
Over 30 ADCs are in clinical development (Table I). The
majority of ADCs are in either Phase I, Phase II or have active
clinical efforts in both Phase I and Phase II (Fig. 1). Only one
ADC, Inotuzumab Ozogamicin, has an active Phase III clin-
ical effort. Over 15 ADCs have been withdrawn from clinical
development for various reasons, which include a lack of anti-
tumor response, unacceptable toxicity or a change in compa-
ny strategy. The results from the clinical development of
ADCs influence the preclinical development efforts,
which lead to the creation of the next generation of
ADCs.
There are several key areas of focus for the preclinical
development of ADCs. These areas include the selection of
an ADC target, the selection of an appropriate antibody and
the selection of appropriate cytotoxic drugs and linkers. Fur-
thermore, attention has to be given to characterizing the
physiochemical properties of the ADCs, evaluation of the
in vitro cytotoxicity, the in vivo anti- tumor efficacy of the ADCs,
the pharmacokinetic properties of the ADCs and their
toxicology/safety profiles (Fig. 2).
TARGET SELECTION
The optimal selection criteria for cell surface tumor antigens
are that the antigen should be expressed selectively and at
higher levels by tumors than normal tissues and the antigens
are internalized by the tumor cell. Furthermore it would be
preferred if the tumor antigens are expressed homogeneously
to increase the number of cells killed by the ADC. It is unclear
what the threshold receptor density or the internalization rate
should be for a tumor antigen because the receptor density
and the internalization rates may vary depending on the
tumor antigen and tumor type. Thus far three ADCs have
been approved to treat cancer patients. Those ADCs are
Gemtuzumab Ozogamicin (Mylotarg), which targets CD33
expressing tumors; Adcetris, which targets CD30 expressing
tumors and Kadcyla, which targets Her2 expressing tumors
(Table II).
CD33
CD33 (Siglec-3) is expressed by the precursor myeloid and
monocytic cells. CD33 is expressed in approximately 85–90%
of adult and child AML patients and in 100% of acute
promyelocytic leukemia (APL), which is a subset of
AML (18,19). CD33 expression correlates with poor
prognosis for children with ALL (20). High levels of
CD33 expression have been reported in the bone mar-
row of AML patients while substantially lower levels of
expression have been observed in normal bone marrow
(21). The restricted expression of CD33 in normal tis-
sues and the high levels of expression in AML made
CD33 an attractive therapeutic target.
Three ADCs, Mylotarg, AVE9633, and SGN-CD33A,
have been developed to treat patients with CD33 expressing
tumors.
AVE9633 was a humanized IgG1 antibody conjugated
to an average of 3–5 molecules of N2′-deacetyl-N2′-(4-
mercapto-4-methyl-1-oxopentyl)-6-methylmaytansine
(DM4) via a hindered disulfide linker on lysines. In pre-
clinical studies, AVE9633 selectively killed AML cell lines
and AML patient samples in vitro (22,23). Three phase I
studies were performed and a total of 54 AML patients
were treated with AVE9633. Patients were treated on day
1 of a 21 day cycle (Day 1), days 1 and 8 (Day 1/8) and
days 1, 4 and 7 (Day1/4/7) of a 28 day cycle. The day 1
and day1/4/7 schedules were terminated early due lack
of cytotoxic activity at doses higher than the doses that
saturated binding to CD33 (22).
Mylotarg, as was previously mentioned, was removed from
the market in 2010, which leaves SGN-CD33A as the only
ADC currently in clinical development against CD33. SGN-
CD33A is composed of humanized IgG1 antibody (h2H12),
which contains two engineered cysteines at position 239
(S239C) on the antibody heavy chains. The DNA synthesis
inhibitor, made by the former Spirogen LTD (now Astra-
Zeneca/MedImmune), pyrrolobenzodiazepine (PBD), is co-
valently conjugated to each site specific cysteine using the
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maleimidocaproyl-valine-alanine linker. SGN-CD33A is the
first publically disclosed site specific ADC in clinical
development.
CD30
CD30 (TNFRSF8) is expressed on activated T and B cells and
a small population of eosinophils. It is also expressed in
sALCL, HL, mature T cell lymphomas and B cell derived
non-Hodgkins lymphoma (NHL). sALCL is a rare type of
NHL, comprising approximately 3% of all NHL but is one
of the more common T cell lymphomas (24). CD30 is
expressed uniformly on sALCL (25). A soluble form of
CD30 has been reported in the sera of cancer patients but
this does not seem to have a deleterious effect on Adcetris (26).
Limited expression of CD30 has been reported in normal
tissues and high expression has been reported in sALCL, HL
and other malignancies (27).
Adcetris had objective response rates of 75% for Hodgkin’s
lymphoma (HL) patients and 86% for sALCL patients.
Table I ADCs in Clinical Development
ADC Target Phase of Development Indication Isotype Payload
ABT-414 Activated EGFR/EGFRvIII Phase I GBM, SCC IgG1 MMAF
AGS16M8F ENPP3 Phase I RCC IgG2 MMAF
ASG22M6E Nectin 4 Phase I Solid tumors IgG1 MMAE
AGS67E CD37 Phase I NHL, CLL, AML IgG2 MMAE
AMG 172 CD27L Phase I RCC IgG1 DM1
AMG-595 EGFRvIII Phase I GBM ND DM1
ASG15E SLITRK6 Phase I Solid tumors IgG2 MMAE
Bay 94-9343 Mesothelin Phase I Solid tumors IgG1 DM4
BT-062 CD138 Phase I/II Multiple myeloma IgG4 DM4
Glembatumumab Vedotin (CDX-011) GPNMB Phase II Breast cancer IgG2 MMAE
IMGN-853 FOLR1 Phase I Solid tumors IgG1 DM4
IMMU-130 CEACAM5 Phase I Colorectal IgG1 SN-38
IMMU-132 TACSTD2 (TROP2) Phase I Epithelial cancer IgG1 SN-38
IMGN529 CD37 Phase I NHL, CLL IgG1 DM1
Inotuzumab Ozogamicin (CMC-544) CD22 Phase III ALL IgG4 CalichDMH
MDX-1203 CD70 (MDX-1115) Phase I Clear cell RCC, B-NHL ND CC-1065
Milatuzumab CD74 Phase I/II Multiple myeloma IgG1 Doxorubicin
MLN0264 Guanylyl cyclase C Phase I Colorectal ND MMAE
PF-0626350 5T4 Phase I Solid tumor ND MMAF
PSMA (BrUOG 263) PSMA Phase I/II Prostate IgG1 MMAE
RG7450 (DSTP3086S) STEAP1 Phase I Prostate ND MMAE
RG7458 (DMUC5754A) MUC16 Phase I Ovarian IgG1 MMAE
RG7593 (DCDT2980S) CD22 Phase I NHL IgG1 MMAE
RG7596 (DCDS4501A) CD79b Phase I/II NHL IgG1 MMAE
RG7598 ND Phase I ND ND Undisclosed
RG7599 (DNIB0600A) NaPi2b Phase I Ovarian, NSCLC IgG1 MMAE
RG7600 ND Phase I ND ND ND
RG7636 Endothelin B receptor Phase I Melanoma ND MMAE
SAR3419 CD19 Phase I DLBCL, ALL IgG1 DM4
SAR566658 CA6 Phase I Solid tumor IgG1 DM4
SC16LD6.5 Fyn3 Phase I/II SCLC ND D6.5
SGN-CD19A CD19 Phase I ALL, NHL ND MMAF
SGN-CD33A CD33 Phase I AML IgG1 PBD (SGD-1882)
SGN-LIV1A LIV-1 Phase I Breast cancer ND MMAE
ND not disclosed, SN-30 7-ethyl-10-hydroxycamptothecin, PBD Pyrrolobenzodiazepine,MMAEMonomethylauristatin E,MMAFMonomethylauristatin F, GBM
Glioblastoma multiforme, RCC Renal cell cancer, SCLC Small cell lung cancer, NSCLCNon-small cell lung cancer, AML Acute Lymphoblastic Leukemia,NHLNon-
hodgkin lymphoma, ALL Acute lymphoblastic leukemia, DLBCL Diffuse large B-cell lymphoma, SCC Squamous cell carcinoma
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Tumor reductions were reported in 94% of the HL patients
and 97% of the sALCL patients (28). Interestingly CD30
expression in diffuse large B cell lymphoma (DLBCL) patients
did not correlate with patient response to Adcetris. Tumor
responses were observed in DLBCL patients that had unde-
tectable expression of CD30 via immunohistochemical evalu-
ation (29). These data suggest that CD30 expression alone in
DLBCL patients may not predict response to Adcetris. It also
suggests that low CD30 expression is sufficient for responses to
Adcetris.
Her2 (ERBB2)
Unlike CD33 and CD30, which are predominately expressed
by hematological malignancies, Her2 is predominantly
expressed by solid tumors. In particular, it is expressed in
breast, gastric and ovarian cancer amongst others. Her2 is
over expressed by approximately 25% of patients with inva-
sive breast cancer. It is uniformly expressed in breast cancer
and high expression of Her2 correlates with poor prognosis
(30–33). Her 2 is also expressed by several normal tissues
including, the skin, respiratory tract, heart, gastrointestinal
epithelial cells and in the urinary and reproductive tracts
(34). Kadcyla, also known as T-DM1, was approved in 2013
for Her2 expressing late stage breast cancer patients. The
objective response rate in the pivotal EMILIA trial was
43.6% for patients treated with Kadcyla and 30.8% for pa-
tients treated with lapatinib and capecitabine (35).
Solid Tumor Antigens
Developing antibody therapeutics for targets expressed in
solid tumors may offer some additional challenges that may
Fig. 1 Clinical development of ADCs.
Antibody Generation Antibody Characterization
In vitro cytotoxicity
Target ID
Pharmacokinetics In vivo Tumor Efficacy
• High and homogeneous 
expression in the majority 
of patient tumors.
• Low expression in normal 
tissues.
• Target is internalized.
• Use mice or phage display 
methods to generate 
antibodies.
• Generate sufficient 
quantities of antibody.
Conjugation
• Binds with high affinity to 
the human antigen.
• Specific for the antigen.
• Evaluate the ability to bind 
to rodent and non-human 
primate versions of the 
antigen. 
• No sequence 
abnormalities.
• Optimization of conditions
• Low aggregation.
• High monomeric content.
• Consistent DAR.
• High yield.
• No loss of binding affinity.
• Kills antigen expressing 
cells. (low nM-pM IC50
values)
• Does not kill non-antigen 
expressing cells.
• Kills cells with known drug 
resistance mechanisms.
In vivo Toxicology
• Has minimal release of the 
payload in serum (in vitro).
• Has minimal release of the 
payload in the serum of 
rodents (tumor bearing 
and non tumor bearing).
• Has minimal release of the 




properties (i.e. T1/2, AUC)
• Induces tumor stasis or 
regression in multiple 
human tumor models. 
(Cell line xenografts, PDX, 
GEMMs)
• No obvious signs of 
toxicity at efficacious 
exposures.
• Not efficacious in non-
antigen expressing tumors.
• Identify the MTD and DLTs in 
rodents and non-human 
primates.
• Determine the serum 
exposures where DLTs were 
observed. (Toxicokinetics)
• Histological analysis of tissues.
• Analysis of blood chemistry.
• Is the toxicity reversible, 
manageable and can it be 
monitored?
a Creating the ADC
b Testing the ADC
Fig. 2 Preclinical development and evaluation of ADCs.
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not exist for hematological cancer targets. For hematological
cancers, it is possible to determine the dose that achieves
receptor saturation. Once that dose is achieved, the addition
of higher amounts of ADC would not be beneficial. Antibody
delivery to solid tumors, however, is very complex. Solid
tumors have high intratumoral pressures, due to the lack of
lymphatics (36). Solid tumors have leaky blood vessels and
chaotic blood flow, which can result in heterogeneous distri-
bution of the antibody within the tumor thus rendering por-
tions of the tumor inaccessible to the antibody or ADC
(36–38). Another factor to consider is the large size of anti-
bodies, which have a molecular weight of ~150 kD. The large
size of the antibodies may limit their ability to efficiently
penetrate deep within a solid tumormass thus leaving portions
of the tumor untreated and free to continue to grow (39). In
addition to the physical properties of the antibody, the expres-
sion of the antigenmust also be taken into consideration. If the
tumor antigen is heterogeneously expressed within the tumor,
portions of the tumor could be devoid of ADC thus allowing
portions of the tumor to be untreated, which enables tumor
growth. Lastly antibody affinities may impact anti-tumor effi-
cacy of an ADC. Antibodies with high affinities are tightly
bound to the antigen and may be unable to penetrate the
tumor as well as antibodies with lower affinities, which will
reduce the effectiveness of the ADC (40,41).
The current operating hypothesis is an ADC must be
internalized in order for the drug to be released from the
antibody and subsequently kill the antigen expressing cell.
This has resulted in linkers that are designed to release their
drug in a low pH environment or upon proteolysis using
lysosomal enzymes. Although this is one way ADCs function,
it is possible that some ADC drugs could be released without
be ing in te rna l i zed . The ant i -CEACAM5 ADC
(Epratuzumab-SN-38), which uses the CL2A linker combined
with the SN-38 drug, has been reported to deliver the ADC to
the antigen expressing tumors in vivo but releases the SN-38
drug without being efficiently internalized (42). The authors
state that SN-38 is slowly released from the anti-CEACAM5
antibody (@50%/day) and the in vitro internalization rate for
the anti-CEACAM5 antibody is slow. However, it is not clear
that in vitro rates of internalization necessarily predict in vivo
rates. Thus, the use of pH sensitive dyes (i.e. pHRodoTM) or
far red dyes to label ADCs to evaluate the internalization and
intracellular trafficking of ADCs in vivo, could be a useful tool




The first ADCs were developed using murine antibodies.
Patients developed HAMA responses against the murine an-
tibody, which may have limited the effectiveness of these
ADCs (3). The majority of the ADCs currently in clinical
development are chimeric, fully human or humanized IgG1
antibodies. IgG2 and IgG4 isotypes are also being developed
as ADCs (Table I).
There are structural differences between the various anti-
body isoforms (Fig. 3). The IgG2 isotype has four interchain
disulfide bonds in the hinge region while the IgG1 and IgG4
isoforms have two interchain disulfide bonds (Fig. 3). The
conjugation of the cytotoxic drug to the antibody, on cyste-
ines, requires a partial reduction of the disulfides in the hinge
region of the antibody. Tris (2-carboxyethyl)-phosphine
(TCEP) is commonly used to reduce the antibody thus in-
creasing the number of free thiols available for conjugation.
IgG2 antibodies require higher concentrations of TCEP and
longer reaction times than is required for IgG1 antibodies
(43). Furthermore the IgG2 isoform exists as an A form, a B
form and a hybrid A/B form (44). The significance of how
these different IgG2 isoforms affect the production or conju-
gation of a drug to an ADC is unclear.
Some IgG1 antibodies have antibody-dependent cellular
cytotoxicity (ADCC) and complement dependent cytotoxicity
(CDC), which is achieved through binding of the antibody’s
Fc domain to the Fcγ receptors on natural killer cells, mono-
cytes and macrophages (45). IgG2 and IgG4 antibodies have
little to no CDC activity (46). Although IgG1 antibodies, such
as Trastuzumab, can have ADCC and CDC activities, it is
unclear whether these activities are important for an ADC
(47). To address the potential differences between IgG1, IgG2
and IgG4 ADCs, an anti-CD70 ADC, which was conjugated
to valine-citrulline monomethyl auristatin F (MMAF) (43).
Table II List of Approved ADCs
ADC Target Isotype Payload Indication Date of Approval
Mylotarg CD33 IgG4 Calicheamicin AML 2000 (US) a
Kadcyla (T-DM1) Her2 IgG1 DM1 Her2 positive late stage breast 2013 (US)
Adcetris (SGN-35) CD30 IgG1 MMAE sALCL, relapsed/refractory Hodgkin lymphoma 2011 (US)
AML Acute Lymphoblastic Leukemia, ACLC Anaplastic large cell lymphoma
a Withdrawn in 2010
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The authors also mutated the Fc domains of the anti-CD70
IgG1 (IgG1v1) and IgG4 (IgG4v1) ADCs to reduce binding
affinity to the Fcγ receptors. The IgG1v1-vc4 ADC had better
in vivo tumor efficacy than the native IgG1-vcF4 ADC, which
was attributed to increased serum exposure of the Fc mutated
IgG1 ADC. This provided only a partial explanation for the
enhanced efficacy of the Fc mutated IgG1 ADC because the
wild type IgG2-vcF4 ADC had comparable serum exposure
as the Fc mutated IgG1 ADC yet it was not as efficacious as
the mutated IgG1 ADC.
CYTOTOXIC DRUGS AND LINKERS
Cytotoxic Drugs
The drugs used for ADCs inhibit cellular processes that are
vital for cell proliferation and/or survival, such as tubulin
polymerization or DNA replication (Table III). Inhibition of
tubulin function or DNA synthesis induces apoptotic cell
death. The current cytotoxic drugs, used as ADC payloads,
are typically 100–2,000 fold more potent than doxorubicin,
vinca alkaloids or taxanes (48–51). Although the majority of
drugs in clinical development inhibit tubulin function or DNA
synthesis, new drugs which inhibit critical cellular processes,
such as RNA synthesis or membrane disruption are being
developed as ADC payloads and may enter into clinical
development. The cytotoxic drugs or their metabolites have
varying degrees of membrane permeability. MMAE, for ex-
ample, is membrane permeable and when released from a cell
it may kill neighboring cells by a process known as bystander
effect (52). MMAF has reduced membrane permeability and
the metabolite, Cys-mcMMAF, does not exhibit bystander
activity. Bystander activity may be useful in a solid tumor
setting when the target antigen is heterogeneous expressed in
the tumor. An anti-mesothelin ADC, Anetumab ravtansine,
which is a fully human anti-mesothelin antibody conjugated to
an average of 3.2 molecules of the cytotoxic maytansine drug
DM4, was reported to exhibit bystander activity in tumor
xenograft models (53). Tumor regressions were observed in
tumor models where only 20% of the cells expressed
mesothelin, which suggests that the non-mesothelin cells were
killed by the release of the DM4 metabolite from the
mesothelin expressing cells.
Linkers
Linkers are grouped into two classes (Table IV). They are
either cleavable or non-cleavable. Cleavable linkers can be
dipeptide linkers, such as valine-citrulline, and are cleaved by
proteases (i.e. Cathepsin B), which results in the release of the
cytotoxic drug. Cleavable linkers can also be acid labile, such
as hydrazones and hindered disulfides, where the lysosomal
environment results in the release of the cytotoxic drug. ADCs
with non-cleavable linkers are degraded in the lysosome,
which results in the formation of an amino acid-drug combi-
nation (i.e. Cys-mcMMAF). Although the linkers can be proc-
essed by the enzymes or environment of the lysosome, some
linkers such as maleimide linkers, can transfer the cytotoxic
drug to free sulfhydryls such as the cysteine on human serum
albumin (HSA) or glutathione via a retro-michael reaction
(54,55). This can cause a 25% or greater decrease in the
tumor exposure of the ADC (54). This decrease in tumor
exposure may reduce the effectiveness of the ADC.
The linker/drug combination can influence the pharma-
cokinetics and the toxicology profile of the ADC. A human-
ized antibody (huC242) against CanAg/MUC1 was conju-
gated to the SPP-DM1 and SPDB-DM4 linker/drug combi-
nations and evaluated in preclinical and clinical studies
(Table V). The serum half-life in humans for the huC242-
SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing
schedule, ranged between 18 and 48.5 hrs while the serum
half-life for huC242-SPDB-DM4 (IMGN242) was between
60 and 120 hrs (56). In addition to the apparent differences
in the half-lives of the ADCs, the dose limiting toxicities (DLT)
Fig. 3 IgG isotypes used as ADCs.
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were also different. The DLT for the huC242-SPP-DM1
ADC was elevated hepatic transaminase and the DLT for
the huC242-SPDB-DM4ADCwas ocular toxicity, which was
only observed in patients with low serum levels of CanAg (56).
These data suggest that the different drug linker combinations
can have significant effects on the pharmacokinetics of the
ADC and the toxicology profiles. Interestingly, several ADCs
have been reported to have reversible ocular toxicity in pa-
tients (Table VI). Ocular toxicity has been observed primarily
for ADCs conjugated to DM4 or MMAF but Kadcyla, which
is conjugated to DM1, reported ocular toxicity in 31.3% of the
patients in a phase II study (57). These observations have
resulted in the inclusion of ophthalmologic evaluation in pre-
clinical toxicology studies. A patent application, US
20120282282 A1, was filed by Immunogen where the claims
suggest that the ocular toxicity for DM4 ADCs can be de-
creased by modifying the charge of the linker. The uncharged
SPDB linker was reported to display decreased ocular toxicity
in a rabbit model than the charged sulfo-SPDB linker.
Drug Resistance
One of the reasons why cancer therapies fail is due to drug
resistance (58). There are several mechanisms responsible for
resistance to chemotherapies, which includes the expression of
drug-efflux pumps (59). Drug-efflux pumps lower the intra-
cellular concentration of the drug which renders the drug
ineffective. The expression of several drug efflux pumps in-
cluding multi-drug resistance 1(MDR1/ABCB1), multi-drug
resistance protein 1(MRP1/ABCC1) and breast cancer resis-
tance protein (BCRP/ABCG2) have been implicated in resis-
tance to various chemotherapeutics. Several cytotoxic drugs,
used for ADCs, such asMMAE,DM1 andCalicheamicin, are
known substrates of the drug efflux pump MDR1 (ABCB1)
(60,61). MDR1 substrates tend to be hydrophobic drugs
therefore modifying the metabolites to be polar or negatively
charged may reduce the drugs from being pumped out of the
cells via MDR1 (62).To counteract the MDR1 drug efflux
pump, the linker used to conjugate DM1 to an anti-EpCam
an t i b ody wa s ch ang ed f r om N- s u c c i n im i d y l -
4-(maleimidomethyl) cyclohexane-1-carboxylate (SMCC) to
the hydrophobic linker PEG4Mal. The resulting metabolite,
lysine-PEG4Mal-DM1 was able to kill MDR1 expressing cells
while the lysine-SMCC-DM1 was unable to kill MDR1 ex-
pressing cells (63). These data suggest that selection of the
appropriate linker may be important to avoid resistance me-
diated via drug efflux pumps. In addition to selecting the
appropriate linker to avoid drug efflux pumps, cytotoxic drugs
Table IV Linkers Used for ADCs
Linker name Cleavable/Non-cleavable Conditions for payload release Payload
Valine-citrulline (vc) Cleavable Protease MMAE
SPP Cleavable Reducing/Oxidizing environment DM1
SPDB Cleavable Reducing/Oxidizing environment DM4
6-maleimidocaproyl hydrazide Cleavable Acid labile Doxorubicin
4-(4′-acetylphenoxy) butanoic acid) Cleavable Acid labile Calicheamicin
CL2A Cleavable pH mediated SN-38
SMCC Non-cleavable Antibody degradation DM1
Maleimidocaproyl (mc) Non-cleavable Antibody degradation MMAF
SPP N-succinimidyl 4-(2-pyridyldithio)pentanoate, SMCC N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate, SPDB N-succinimidyl-
4-(2-pyridyldithio)butyrate, CL2A maleimido-[short PEG]-Lys-PABOCO-20-O-SN-38
Table III ADC Payloads
Drug/Payload (Payload name) Mechanism of action Stage of development
Auristatin (MMAE/MMMAF) Tubulin assembly inhibitor Approved/Clinical
Maytansinoid (DM1/DM4) Tubulin assembly inhibitor Approved/Clinical
Tubulysin Tubulin assembly Inhibitor Preclinical
SN-38 Topoisomerase inhibitor Clinical
Calicheamicin DNA synthesis inhibitor Clinical
Doxorubicin DNA synthesis inhibitor Clinical
Pyrrolobenzodiazepine (SGD-1882) DNA synthesis inhibitor Clinical
Duocarmycin (CC1065) DNA synthesis inhibitor Clinical
D6.5 DNA synthesis inhibitor Clinical
α- Amanitin RNA polymerase II inhibitor Preclinical
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that are not substrates for efflux pumps, such as PBDs, may
also be considered. SGN-CD33A is conjugated to the
PBD,SGD-1882, which is not an MDR1 substrate. SGN-
CD33A can kill MDR1 expressing CD33 positive AML pa-
tient samples and is currently in Phase I.
Several methods, using fluorescent substrates for the vari-
ous drug efflux pumps, have been used to assess the activity of
the pumps and may be useful in characterizing the contribu-
tions of the various pumps to resistance to the ADC metabo-
lites (64). Rhodamine 123, for example, can be used to assess
drug efflux pump activity in cell lines and specific inhibitors of
various efflux pumps can be used to determine the specific
drug efflux pump’s contribution to the efflux activity in a cell
line or patient derived cells (65).
ANTIBODY CONJUGATION OPTIONS
There are two methods used to covalently attach a cytotoxic
drug to an antibody. Currently, the more conventional meth-
od, conjugates the cytotoxic drugs to an antibody’s solvent
exposed cysteine or lysine residues. The site specific conjuga-
tion method conjugates the cytotoxic drugs to natural or non-
natural amino acids that have been engineered at different
locations on the antibody or to glycosyl moieties.
Conventional Conjugation
The majority of the ADCs in clinical development are in this
category. The cytotoxic drugs are conjugated to antibodies via
the thiols on solvent exposed cysteines or the amines on
lysines. The conjugation of cytotoxic drugs to the antibodies
results in a heterogeneous mixture of ADCs where the num-
ber of cytotoxic drugs conjugated to an antibody typically
varies from 0 to 8 drugs per antibody. Antibodies with a
DAR of 8 or more have a higher clearance rate than antibod-
ies with a lower DAR (11). The majority of the ADCs have an
average DAR of approximately 4 drugs per antibody, which
offers an acceptable balance between pharmacokinetic prop-
erties, toxicities and anti-tumor efficacy.
Site Specific Conjugation
Cytotoxic drugs are conjugated to amino acids, typically
cysteines or non-natural amino acids, which have been incor-
porated at distinct locations on the antibody. The resulting
ADC is homogeneous composition where all of the antibodies
contain a defined number of drugs per antibody. Typically a
DAR of 2 is used although higher DARs could be achieved.
The incorporation of a cytotoxic drug on specific positions of
the antibody can influence the pharmacokinetic properties of
the ADC. Several examples of site specifically conjugated
ADCs, using antibodies containing engineered cysteines or
the non-natural amino acid, p-acetyl phenyalanine (pAF),
have reported improved in vitro and in vivo serum stability,
improved pharmacokinetic properties, comparable anti-
tumor efficacy and improved toxicology profiles as compared
to the conventional ADCs (55,66,67). Cytotoxic drugs conju-
gated to pAF via an oxime bond are reported to have im-
proved serum stability when compared to cytotoxic drugs
conjugated to thiols via maleimide (10,55).
One cysteine engineered site specifically conjugated ADC,
SGN-CD33A, is currently in phase I clinical development.
This is probably the first of many site specific ADCs that will
be evaluated in the clinic.
A couple of novel approaches for site-specific conjugation
not requiring molecular engineering of the antibody are cyste-
ine bridging approaches, which can specifically conjugate all of
the cysteines with a definedDAR or½ the number of cysteines
(4 for a typical IgG1), and conjugation of glycosyl moieties.
There are several companies developing site specific con-
jugation technologies but most are currently in preclinical
development (Table VII). This is an exciting area of develop-
ment for ADCs.
Table V Clinical Summary of huC242 ADCs
Antibody Payload Linker Schedule MTD (mg/m2) T1/2 (hours) DLT Clinical Phase
huC242 DM1 SPP Q1W 115 13–41 Elevated hepatic transaminase I
huC242 DM1 SPP Q3W 235 18–48.5 Elevated hepatic transaminase I
huC242 DM4 SPDB Q3W 168 60–120 Reversible ocular toxicity I
huC242 DM4 SPDB Q3W 168 N/A Reversible ocular toxicity II
Table VI ADCs with Ocular Toxicity in the Clinic
Antibody Target Linker Payload
SAR3419 CD19 SPDB DM4
IMGN853 Folate Receptor a SPDB DM4
SGN-75 CD70 mc MMAF
SAR566658 CA6 SPDB DM4
BT-062 CD138 SPDB DM4
huC242-DM4 CanAg SPDB DM4
SGN-CD19A CD19 mc MMAF
Kadcyla Her2 SMCC DM1
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CHALLENGES OF PRECLINICAL DEVELOPMENT
OF ADCS
The data from clinical evaluation of ADCs has led to
significant changes in the preclinical development of
ADCs. The current cytotoxic drugs used as ADC pay-
loads are more potent than methotrexate, doxorubicin
and vinblastine, which were previously used as ADC
payloads. The current sets of linkers, used to conjugate
the drugs to the antibodies, are more stable than the
previous linkers and the amount of unconjugated anti-
body has been dramatically reduced. These changes were
incorporated into the preclinical development of the two
FDA approved ADCs, Kadcyla and Adcetris.
The clinical development of more than 15 ADCs has been
discontinued because the ADCs did not provide sufficient
anti-tumor responses, had unacceptable toxicology profiles
or the company decided to support other products in their
pipeline. These ADCs apparently had an acceptable preclin-
ical data package that supported the decision to progress them
into clinical development. Inotuzumab Ozogamicin (CMC-
544) has an active Phase III clinical effort and is currently the
most advanced ADC in clinical development. CMC-544
showed significant inhibition of tumor growth in various pre-
clinical human B-cell lymphoma cell line models (68). Pfizer,
which is developing CMC-544, recently announced that it is
discontinuing a Phase III trial in NHL but will continue the
Phase III INO-VATE ALL study (B1931022) in ALL. This
suggests that preclinical in vivo anti-tumor efficacy studies may
not predict patient responses to the ADCs and additional
preclinical studies may be warranted to increase the correla-
tion between the data from the preclinical studies and clinical
responses.
An area of focus in the preclinical development of ADCs
could be in improving the tumor models used to evaluate the
ADCs. Preclinical studies have suggested that human tumor
xenografts, derived from cell lines, do not accurately reflect
the original patient tumors they were derived from and may
not predict clinical anti-tumor activity (69,70). Patient derived
tumor xenografts (PDX) are derived from freshly isolated
patient tumors that are implanted, grown and propagated in
immunodeficient mice. A large panel of patient derived colon
tumors was reported to accurately represent the histology and
the range of molecular heterogeneity observed in colon cancer
patients (71). The authors conducted an evaluation of
cetuximab in the colorectal cancer PDX tumors and con-
firmed the key role of KRAS mutation in cetuximab resis-
tance. The increased use of PDX models may provide better
predictive value than the use of human tumor cell lines. ADCs
against 5T4 and tissue factor have reported preclinical in vivo
anti-tumor activity in PDX models (72,73).
Perhaps attention to the pharmacokinetics and pharma-
codynamics of the ADC may add value to the preclinical
effort. An evaluation of a PK/PD modeling approach
reported that tumor growth rate and the ratio between
the exposures and concentrations that induced tumor stasis
were important in predicting tumor responses to Kadcyla
(74). This PK/PD model was modified using the clinical
PK data for Kadcyla and was used to predict the clinically
efficacious exposures for an ADC against the 5T4 tumor
antigen (75). The utility of this modeling approach is cur-
rently being evaluated.
The use of site specific ADCs, improvements in the phar-
macokinetic properties of the ADCs through the development
of better linkers and the use of potent cytotoxic drugs as ADC
payloads combined with improvements in tumor model selec-
tion and target identification may result in higher success rates
for ADCs in the clinic.
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Table VII Companies Developing
Site Specific ADC Technologies Company Type of Technology Stage of Development
Ambrx Inc Non-natural amino acid (NNAA) Preclinical
Genentech/Roche, Novartis Engineered cysteine (Thiomab) Preclinical
Igenica Inc (SNAP ADC) no mutation or NNAA Preclinical
Meditope Bioscience Inc Cetuximab derived residue grafts into Fab Preclinical
Pfizer FXIII substrate peptide - acceptor glutamine Preclinical
Poly Therics Ltd ThioBridge Preclinical
Redwood Bioscience Inc
(acquired by Catalent Pharma Solutions)
Aldehyde tag Preclinical
Seattle Genetics Engineered Cysteine Clinical
Sutro Biopharma Inc Non-natural amino acid Preclinical
SynAffix Glycosyl conjugation Preclinical
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